PCV67 BUDGET IMPACT OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE

Abstract

To evaluate the budget impact of introducing rivaroxaban 2.5mg (RIV) in combination with aspirin 100 mg (ASA) in patients with CAD or PAD in order to assess the affordability of this therapy for the Greek public healthcare system over a 5-year time horizon. The populations modelled reflect the overall COMPASS (NCT01776424) population (CAD or PAD). The model considers the Greek National Healthcare Payer perspective and as such, only direct costs were included. Model inputs included: risk of main events and associated mortality (based on COMPASS); epidemiology data; current and future market share projections for treatments; and data on the following cost items based on national reimbursed prices and DRGs tariffs (e.g. Official Price Bulletin, Government Gazettes): treatment costs, administration costs, disease-related costs (physician visits and laboratory tests), the management cost of potential associated main events, such as myocardial infarction, ischaemic stroke, intracranial haemorrhage, cardiovascular death, bleeding death and the management of potential health events, such as acute limb ischemia, minor and major amputation, and venous thrombo-embolism. Introducing rivaroxaban for the treatment of patients with coronary artery disease or peripheral artery disease in Greece would result in €639,957 and €13,558,417 budget impact in the 1st and 5th year, respectively. The treatment of CAD or PAD with RIV+ASA would have a total net budget impact of €41.6m in five years. Drug cost is the key driver of the increasing total cost. The introduction of rivaroxaban reduces the cost of acute main events, post main events, health events and mortality by €5,173,990 over five years. The progressive introduction of rivaroxaban would result in a manageable budget impact for the Greek healthcare system and represent elevated savings in the management of acute main events, post main events, health events and mortality due to rivaroxaban’s clinical benefits and associated costs.